The Monoamine Oxidase Inhibitors (of which selegiline is one) are well known to be highly effective medicines in the management of depression. However their use has been limited because of their potential for serious side effects. The possible tyramine interactions (which lead to blood pressure increases) with many foodstuffs has largely limited the use of this class to the reserve of last resort.
However by delivering selegiline transdermally and avoiding first pass metabolism (seen with oral dosing) the reaction with foodstuffs is avoided, offering for the first time all the reported benefits that selegiline has to offer without many of the risks.
“MAOIs are well known for the completeness and robustness of their response. Prozac-like drugs can cause headaches, anxiety, apathy, insomnia, nausea and loss of sexual interest. Selegiline is free of such side effects”
Professor Alexander Bodkin, Harvard University
Syntropharma are actively seeking an appropriate partner to assist in the commercialisation of this opportunity in the EU.